#USA #New York #Securities Fraud #Rosen Law Firm #MoonLake

Investors of MoonLake Immunotherapeutics Face Legal Action

In a significant legal development, investors who purchased common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024, and September 29, 2025, have a chance to participate in a securities fraud lawsuit. The Rosen Law Firm, a global law firm dedicated to investor rights, is leading this class action and is reminding affected purchasers of the forthcoming deadline to act.

Important Deadline Approaches

The law firm has highlighted that December 15, 2025, is the last day for investors to apply to become a lead plaintiff in the case. Being a lead plaintiff is crucial, as it entails representing the interests of all class members during the litigation process. The lawsuit aims to provide compensation to those who may have incurred losses due to misleading information disseminated by MoonLake's executives.

What Happened?

The complaint asserts that throughout the specified class period, MoonLake’s management made numerous false statements and withheld critical facts concerning the effectiveness of its leading products. Specifically, it is alleged that there was a failure to adequately differentiate between SLK Nanobodies and BIMZELX monoclonal antibodies, misleading investors about the clinical benefits and efficacy of their treatments.

Key Allegations Include:

1. Misrepresentation regarding shared molecular targets (the inflammatory cytokines IL-17A and IL-17F).
2. Claims that SLK's unique structure would provide significant clinical benefits, which were unfounded.
3. Misleading statements concerning the clinical efficacy of SLK’s supposed advantages over traditional monoclonal structures.

Joining the Class Action

Investors wishing to join the class action lawsuit can do so quickly by visiting the Rosen Law Firm's official page at rosenlegal.com or can contact Phillip Kim, Esq., via toll-free number 866-767-3653. Alternatively, inquiries can be made through email at [email protected].

Choosing the Right Representation

The Rosen Law Firm encourages investors to be judicious in selecting their legal counsel, emphasizing the importance of engaging with law firms that possess substantial experience and a successful track record in handling securities class actions. Given that many firms may merely act as intermediaries, it is crucial for investors to choose a firm actively engaged in litigation.

Background on Rosen Law Firm

The Rosen Law Firm has a fierce reputation in the field of securities litigation. With several landmark cases, including the largest securities class action settlement against a Chinese company to date, their expertise is widely recognized. In 2017, they were rated as having the highest number of settlements in securities class actions, a status they have maintained for years. In 2019, they successfully recovered over $438 million for investors, showcasing their effectiveness in this domain.

Next Steps for Investors

Before joining the class action, investors must understand that no class has yet been certified. As such, until certification is granted, potential litigants are not effectively represented unless they elect to retain counsel. Investors may also choose to remain absent from the action, but participation as a lead plaintiff can yield significant advantages in any financial recovery.

Continued updates can be found by following Rosen Law Firm on their social media platforms, including LinkedIn, Twitter, and Facebook.

Investors in MoonLake Immunotherapeutics should act promptly to ensure their interests are safeguarded in this securities fraud case, aligning with legal experts dedicated to their cause.